PDCD1 and neoplasm: Furthermore, in patients with basal or squamous cell carcinoma treated by PD-1 blockade, pre-existing tumor-specific T cells appeared to have limited reactivation capacity, and response to therapy may have resulted instead from constant attraction of new T cells [96].